NEW YORK, NY / ACCESSWIRE / January 23, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of ...

NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of ...

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Neumora ...

Neumora Therapeutics Inc’s profitability metrics reveal financial health. The company currently boasts a gross margin of -81.35%. The profit margin, also known as the revenue ratio or gross profit ...

Neumora Therapeutics’ phase 3 fail was worse than analysts feared. | Neumora Therapeutics’ phase 3 fail was worse than ...

NMRA opened at $2.17 on Wednesday. Neumora Therapeutics has a 1-year low of $1.83 and a 1-year high of $21.00. The company has a market cap of $350.59 million, a price-to-earnings ratio of -1.16 ...

Neumora Therapeutics, Inc., a Delaware-based company listed on the Nasdaq Global Select Market under the ticker symbol “NMRA,” recently disclosed its latest developments in a Form 8-K filing ...

Neumora Therapeutics Inc (NMRA) stock saw a modest uptick, ending the day at $2.06 which represents a slight increase of $0.01 or 0.49% from the prior close of $2.05. The stock opened at $2.03 and ...

NEW YORK CITY, NY / ACCESS Newswire / January 20, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc.") (NASDAQ ...

Neumora Therapeutics Inc.’s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a treatment for major depressive disorder failed to meet its main goals.

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...